Inhibitor of endocannabinoid cellular reuptake
Provided is a highly potent and selective endocannabioid cellular reuptake inhibitor represented by formula (I): or a pharmaceutically acceptable solvate or co-crystal thereof as well as to a formulation comprising this inhibitor, and to methods of treatment in which this inhibitor is used.
1. A compound represented by formula (I):
or a pharmaceutically acceptable solvate thereof.
2. A formulation, comprising the compound of claim 1 and a pharmaceutically acceptable excipient.
3. A method of treating a mammal suffering from a disease, disorder, or condition, the method comprising administering to said mammal a therapeutically effective amount of a compound represented by formula (I):
or a pharmaceutically acceptable solvate thereof;
wherein said disease, disorder, or condition is one or more of neuropathic pain, peripheral pain, persistent pain, inflammatory pain, or anxiety.
4. The method of claim 3 , wherein said mammal is a primate, equine, canine or feline.
5. The method of claim 3 , wherein said mammal is a human.
6. The method of claim 3 , wherein said compound is administered orally, intravenously, sublingually, ocularly, transdermally, rectally, vaginally, topically, intramuscularly, subcutaneously, buccally or nasally.
7. The method of claim 3 , wherein said compound is administered orally.
8. A method of treating a mammal suffering from a disease, illness or disorder associated with endocannabinoid reuptake, comprising:
administering to said mammal a therapeutically effective amount of a compound represented by formula (I):
or a pharmaceutically acceptable solvate thereof;
wherein said disease, illness, or disorder is pain.
9. The method according to claim 8 , wherein the endocannabinoid is at least one of anandamide or 2-arachidonoyl glycerol.
10. The method of claim 8 , wherein said compound is administered orally.
11. The method of claim 8 , wherein said mammal is a human.
12. The method according to claim 11 , wherein the endocannabinoid is at least one of anandamide or 2-arachidonoyl glycerol.
13. The method of claim 11 , wherein said compound is administered orally or topically.
14. The method of claim 3 , wherein said disease, disorder, or condition is anxiety.